| Literature DB >> 32415506 |
Abel Po-Hao Huang1,2, Yi-Hua Hsu1, Meng-Shiue Wu3, Hsin-Han Tsai1, Chia-Yi Su1, Thai-Yen Ling3, Shan-Hui Hsu2, Dar-Ming Lai4,5.
Abstract
Spontaneous intracerebral hemorrhage (ICH) is a common disease associated with high mortality and morbidity. The treatment of patients with ICH includes medical and surgical interventions. New areas of surgical intervention have been focused on the evacuation of hematoma through minimally invasive neurosurgery. In contrast, there have been no significant advances in the development of medical interventions for functional recovery after ICH. Stem cells exert multiple therapeutic functions and have emerged as a promising treatment strategy. Herein, we summarized the pathophysiology of ICH and its treatment targets, and we introduced the therapeutic mechanisms of stem cells (e.g. neutrotrophy and neuroregeneration). Moreover, we reviewed and summarized the experimental designs of the preclinical studies, including the types of cells and the timing and routes of stem cell administration. We further listed and reviewed the completed/published and ongoing clinical trials supporting the safety and efficacy of stem cell therapy in ICH. The limitations of translating preclinical studies into clinical trials and the objectives of future studies were discussed. In conclusion, current literatures showed that stem cell therapy is a promising treatment in ICH and further translation research on judiciously selected group of patients is warranted before it can be extensively applied in clinical practice.Entities:
Keywords: Clinical trial; Hemorrhagic stroke; Intracerebral hemorrhage; Preclinical study; Stem cell therapy; Translational medicine
Mesh:
Year: 2020 PMID: 32415506 DOI: 10.1007/s11033-020-05457-9
Source DB: PubMed Journal: Mol Biol Rep ISSN: 0301-4851 Impact factor: 2.316